Sermorelin for Adults 65 and Older: Transitioning Safely Into Geriatric Care

What sermorelin is, and what it was once approved for

Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone, described in a 1999 review as the shortest synthetic peptide with the full biological activity of GHRH [5]. It acts on the pituitary's GHRH receptor to make the body release its own growth hormone, and it is not growth hormone itself [5].

Geref reached the US market under two applications: a 0.05 mg/ampule product approved December 28, 1990 for evaluating the pituitary's ability to secrete growth hormone, and 0.5 mg and 1 mg vials approved September 26, 1997 for treating idiopathic growth hormone deficiency in children with growth failure [1]. Geref was not approved for adults, anti-aging, weight loss or athletic performance [1].

The manufacturer discontinued both products in 2008 and asked FDA to withdraw the applications, and FDA withdrew both approvals effective June 18, 2009 [1]. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [1]. Sermorelin products available today, including sermorelin, are compounded, and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [2][7].

The two studies that gave GHRH to older men

Fourteen days at two doses (Corpas, JCEM 1992)

Ten healthy men with a mean age of 68 took 0.5 mg and 1 mg GHRH(1-29) subcutaneously twice daily for 14 days each, in random order, and were compared with nine men with a mean age of 26 [3]. At baseline the older men had lower IGF-I and a shorter mean peak duration of spontaneous growth hormone release [3]. At the 1 mg twice-daily dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the young men. Significant rises from the older men's own baseline in several growth hormone measures and in IGF-I were reported only at the high dose [3].

Six weeks at 2 mg nightly (Vittone, Metabolism 1997)

Eleven men aged 64 to 76 with low baseline IGF-I injected 2 mg GHRH subcutaneously at home each night for six weeks [4]. Nocturnal growth hormone release, the area under the growth hormone peak and peak amplitude all rose [4]. IGF-I, IGF binding protein-3 and growth hormone binding protein did not change [4]. Two of six strength measures (upright row and shoulder press) and one endurance test (abdominal crunch) improved; weight, BMI, waist-to-hip ratio, DEXA measures of muscle and fat, muscle histology, lipids, and glucose, insulin and growth hormone responses to an oral glucose tolerance test did not [4].

How the two regimens differed

Corpas used 1 to 2 mg a day split into two injections and saw IGF-I reach levels not significantly different from young men; Vittone used a single 2 mg nightly injection and saw no change in IGF-I or growth hormone pulse frequency [3][4]. The studies also differed in length and in the men enrolled, so the IGF-I difference cannot be pinned on any one of those factors.

Is there a dose change at 65?

Nothing in the regulatory record creates one. The three regimens that appear in the literature were designed for three different groups: 30 micrograms per kg once daily subcutaneously at bedtime in the pediatric program [8], 0.5 mg or 1 mg twice daily for 14 days in the older-men physiology study [3], and 2 mg nightly for six weeks in the second older-men study [4]. None of these is a recommended dose.

What the studies reported about tolerability and metabolic measures

The largest sermorelin safety dataset comes from children, not older adults. In the one-year pediatric study of 110 previously untreated children (86 eligible for the efficacy analysis), 30 micrograms per kg subcutaneously at bedtime produced no adverse changes in general biochemistry or hormone tests, fasting glucose did not change, IGF-I was not excessively raised, and the drug was well tolerated overall [8]. Those findings come from children with growth hormone deficiency and do not describe adults over 65.

In the six-week older-men study, glucose, insulin and growth hormone responses to an oral glucose tolerance test were unchanged, and lipids were unchanged [4]. A six-week study with no change in glucose does not establish what happens over months or years.

Timing of the injection

The pediatric program dosed once daily at bedtime [8], and the Vittone study used a single nightly injection [4]. After an intravenous dose in 30 healthy men aged 19 to 43, GHRH(1-29) was eliminated quickly, yet growth hormone levels stayed raised for about three hours [9].

Compounded status and sport

Sermorelin does not appear on FDA's page of bulk substances that may present significant safety risks when compounded [10]. On FDA's list of bulk substances nominated for outsourcing facilities (updated March 21, 2025) it sits in category 1, under evaluation, and carries the list's symbol for bulk substances that are components of FDA-approved drugs [11]. It does not appear in any category on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [12][13].

WADA's 2026 Prohibited List names sermorelin in S2.2.4 among growth hormone releasing factors, prohibited at all times in and out of competition, and it is named again in the 2027 List [6][14].

What the older-adult data cannot show

Both older-men studies enrolled healthy men and lasted 14 days and six weeks. They cannot describe effects over a year or longer, effects in older adults with other conditions, or outcomes such as falls, fractures or interactions with other medicines.